Project Grant 201233522199351

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $300,000 to Planet Biotechnology Incorporated for the development of Factor H-Fc fusion proteins as a pre-exposure prophylactic treatment against Rickettsia infections. The goal is to engineer these fusion proteins to enhance immune system recognition and killing of Rickettsia bacteria, which cause dangerous acute...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $300,000 to support the development of a novel preventive treatment for Lyme disease and relapsing fever. The awardee, Planet Biotechnology Inc., is leveraging its expertise in plant-based protein production to engineer and optimize a fusion protein, FC3/SCR(19-20), that can block the transmission of disease-causing...

This $3,454,926 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to define the optimal pathway from antibody precursors to broadly neutralizing antibodies (bNAbs) targeting the HIV-1 envelope glycoprotein apex epitope. The research aims to refine the understanding of common apex bNAb precursors found in uninfected individuals and identify SOSIP-TM antigens that can...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $760,318 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of California, Davis (UC Davis) to develop recombinant enhanced antiviral sensors (REAVRS) that can broadly inhibit known and emerging viruses. The grant aims to generate optimized REAVR proteins, identify virus-induced promoters in mosquito cells, and engineer REAVR-expressing mosquitoes to test their...

This Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to define the immunogenic landscape of early mosquito-stage Plasmodium falciparum parasites in order to accelerate the discovery of malaria transmission-blocking vaccines. The $3,762,999 award, effective July 5, 2024 through May 31, 2029, will support comprehensive proteomic analysis of P. falciparum gametes,...

This $504,703 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to further optimize and integrate the "UltraPCR" platform for detecting and quantifying Trypanosoma cruzi, the parasite that causes Chagas disease. The key objectives are to increase the sensitivity and dynamic range of PCR-based detection of T. cruzi DNA in clinical samples, enabling more accurate...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $309,095 to develop enhanced computational methods for discovering regulatory regions called "enhancers" within the genomes of disease-carrying vector insects. The goal is to enable more targeted gene expression studies and improve strategies for vector control. The award will leverage single-cell ATAC-seq...

This $811,009 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will fund research to develop a new microfluidic device called the Shear-Force Avidity-based Cell Selector (SACS) to directly measure the functionality of memory B cells in response to influenza infection. The primary objectives are to enhance the SACS device design and optimize its ability to capture and separate B...

This $606,815 Cooperative Agreement awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to engineer paratransgenic bacterial strains that can interfere with the ability of mosquitoes to transmit malaria parasites. Specifically, the project will: Engineer Asaia bogorensis bacterial strains that contain no antibiotic resistance genes, are highly resistant to horizontal transfer, and secrete effector proteins to optimize...

This $737,761.00 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) aims to enhance HIV prevention with a vaccine approach that promotes durable immunity. The key products and services to be delivered include: Detailed immune analyses to uncover mechanisms of effective T follicular helper (Tfh) cell-mediated humoral immunity against HIV, using both DNA and mRNA vaccine platforms in rhesus macaques. The...